Aquestive Therapeutics is a clinical-stage biotech firm developing gene-editing therapies for rare diseases via strategic partnerships, recently raising capital to fuel R&D expansion.
Investors might buy AQST for early exposure to a proprietary gene-editing platform targeting lucrative orphan disease markets with limited competition. The recent capital raise of $102.6M provides a runway to advance clinical programs toward pivotal trials and potential first-in-class approvals. If the AVEP platform succeeds, the company could unlock massive value from milestone payments and royalties in a fragmented rare disease landscape.
The stock carries extreme risk due to negative shareholders' equity of $33.7M and a history of escalating losses from $-54.4M in 2022 to $-83.8M in 2025. Revenue volatility, dropping from $57.6M to $44.5M recently, coupled with massive operating expenses of $97.0M, indicates an unsustainable burn rate without successful commercialization. Investors should avoid the stock until clinical data validates the platform or the company demonstrates a clear path to positive cash flow.
Aquestive Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for rare genetic diseases, primarily leveraging its proprietary AVEP platform. The company serves markets across the United States and Europe through its strategic partnerships in orphan drug development. Key products are currently in various stages of clinical development with significant potential in high-value orphan indications.
Despite a significant net loss of $83.8M in 2025, the company successfully increased its cash position from $71.5M to $121.2M through substantial financing activities. However, revenue declined from $57.6M in 2024 to $44.5M, while operating expenses surged to $97.0M, indicating aggressive R&D spending that outpaced commercial growth. The widening net loss suggests the company is prioritizing asset building and clinical progression over short-term profitability.
The rare disease therapeutics sector is characterized by high failure rates but enormous potential rewards due to orphan drug exclusivity periods and limited competition. Companies in this space typically operate with negative earnings and rely on external funding until product approvals are secured. Technological advancements in gene editing are accelerating the pipeline, though regulatory hurdles remain significant for novel mechanisms of action.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $47.7M | $50.6M | $57.6M | $44.5M |
| Cost of Revenue | $0 | $20.8M | $17.9M | $18.6M |
| Gross Profit | $47.7M | $29.8M | $39.7M | $26.0M |
| Operating Expenses | $89.7M | $44.9M | $70.5M | $97.0M |
| Operating Income | $-42.1M | $-15.1M | $-30.8M | $-71.1M |
| R&D | $17.5M | $13.1M | $20.3M | $17.2M |
| G&A | $52.9M | $31.8M | $50.2M | $79.8M |
| Stock-Based Comp | $4.4M | $2.7M | $7.1M | $7.6M |
| D&A | $2.4M | $1.3M | $718.0K | $548.0K |
| Depreciation | $2.3M | $1.2M | $640.0K | $548.0K |
| Amortization | $116.0K | $157.0K | $78.0K | $0 |
| Other OpEx | $19.4M | $0 | $0 | $0 |
| Non-Operating Income | $-12.3M | $7.5M | $-13.4M | $-12.7M |
| Interest Expense | $6.6M | $6.3M | — | — |
| Pre-Tax Income | $-54.4M | $-7.6M | $-44.2M | $-83.8M |
| Income Tax | $0 | $245.0K | $-14.0K | $0 |
| Continuing Ops | $-54.4M | $-7.9M | $-44.1M | $-83.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-54.4M | $-7.9M | $-44.1M | $-83.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-54.4M | $-7.9M | $-44.1M | $-83.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $39.9M | $41.0M | $88.2M | $149.3M |
| Inventory | $5.8M | $6.8M | $6.0M | $6.2M |
| Prepaid Expenses | $2.1M | $1.9M | $3.3M | $4.2M |
| Other Current Assets | $32.0M | $32.3M | $78.9M | $138.9M |
| Long-Term Assets | $17.2M | $16.5M | $13.2M | $11.2M |
| PP&E (Net) | $4.1M | $4.2M | $3.8M | $3.9M |
| Operating Leases | $5.2M | $5.6M | $5.2M | $4.6M |
| Other LT Assets | $7.9M | $6.7M | $4.2M | $2.6M |
| Total Assets | $57.1M | $57.4M | $101.4M | $160.4M |
| Current Liabilities | $39.5M | $18.3M | $18.9M | $47.6M |
| Accounts Payable | $9.9M | $8.9M | $10.3M | $29.9M |
| Current Leases | $255.0K | $390.0K | $510.0K | $631.0K |
| Deferred Revenue | $1.5M | $1.6M | $1.0M | $1.1M |
| Other Current Liab | $19.8M | $944.0K | $1.1M | $11.0M |
| Long-Term Liabilities | $136.1M | $145.6M | $142.7M | $146.5M |
| LT Operating Leases | $5.1M | $5.4M | $5.0M | $4.3M |
| Other LT Liab | $80.9M | $107.8M | $117.7M | $112.8M |
| Total Liabilities | $175.6M | $163.9M | $161.6M | $194.1M |
| Shareholders' Equity | $-118.6M | $-106.5M | $-60.2M | $-33.7M |
| Paid-In Capital | $192.6M | $212.5M | $303.0M | $413.2M |
| Retained Earnings | $-311.2M | $-319.1M | $-363.2M | $-447.0M |
| Total L&E | $57.1M | $57.4M | $101.4M | $160.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-54.4M | $-7.9M | $-44.1M | $-83.8M |
| Non-Cash Adjustments | $27.3M | $1.3M | $21.5M | $-432.0K |
| Working Capital Changes | $17.3M | $203.0K | $-13.1M | $31.8M |
| Cash from Operations | $-9.8M | $-6.4M | $-35.8M | $-52.4M |
| Capital Expenditures | $1.0M | $995.0K | $159.0K | $562.0K |
| Cash from Investing | $-2.5M | $-995.0K | $-159.0K | $-562.0K |
| Cash from Financing | $11.6M | $4.0M | $83.6M | $102.6M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-751.0K | $-3.4M | $47.7M | $49.6M |
| Beginning Cash | $28.0M | $27.3M | $23.9M | $71.5M |
| Ending Cash | $27.3M | $23.9M | $71.5M | $121.2M |
The company's revenue primarily stems from collaboration agreements and milestone payments related to its lead programs targeting rare genetic conditions. Financials indicate heavy investment in research and development ($17.2M) alongside general and administrative costs ($79.8M), typical of a pre-commercialization biotech entity with no commercial product sales yet.
The company faces substantial dilution risk given its negative equity of $33.7M and reliance on recent financing inflows of $102.6M to sustain operations. High cash burn rates, with operating expenses at $97.0M against only $44.5M in revenue, threaten liquidity if future capital raises fail or clinical trials underperform. Regulatory approval uncertainties for gene-editing therapies could delay commercialization timelines indefinitely. Dependence on a single platform and partnership ecosystem creates concentration risk if key collaborations terminate.
Aquestive possesses a unique proprietary gene-editing platform (AVEP) designed to address previously untreatable rare genetic diseases. The company benefits from strategic partnerships that de-risk development and provide upfront funding, reducing immediate cash burn pressure. Its focus on high-value orphan indications offers significant market exclusivity potential upon regulatory approval.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.